

**amantadine extended-release tablet (OSMOLEX ER)**

**Diagnosis Considered for Coverage:**

- Parkinson's disease
- Drug-induced extrapyramidal symptoms (EPS)

**Coverage Criteria:**

**For Parkinson's disease:**

- Patient is currently taking immediate-release amantadine and wishes to use extended-release amantadine formulation, **and**
- Dose does not exceed 322 mg per day.

**For drug Induced extrapyramidal symptoms:**

- Patient is currently taking immediate-release amantadine and wishes to use extended-release amantadine formulation, **and**
- Dose does not exceed 322 mg per day.

**Coverage Duration:** one year

Effective Date: 11/02/2023